Skip to content

Efficacy of Adductor Channel Block for anterior cruciate ligament surgery: A prospective double blinded randomized controlled trial

Efficacy of Adductor Channel Block for anterior cruciate ligament surgery: A prospective double blinded randomized controlled trial - DUAL trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON51570
Enrollment
34
Registered
2022-06-02
Start date
2022-08-25
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anterior cruciate ligament rupture

Interventions

Identification of the adductor channel using ultrasonic landmarks such as the femoral artery and the sartorius muscle. When a patient is randomized in the intervention group
10 ml of Levobupivacaine 0.25% will be added in the adductor channel. When randomized in the control group: 10 ml of sodium chloride 0.9% (placebo) will be added in the adductor channel.

Sponsors

Sint Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - ASA classification 1-3 - Age >= 18 years - Anterior cruciate ligament surgery - General anesthesia - Informed consent

Exclusion criteria

Exclusion criteria: - Contraindication to local anesthetics - Neuromuscular disease

Design outcomes

Primary

MeasureTime frame
The primary endpoint is postoperative pain (numerical rating score) within the first 24 hours

Secondary

MeasureTime frame
Secondary endpoints are pain score 48 hours postoperative, motor block result, use of postoperative pain medication including opiates and the use of rescue medication, postoperative pain location, postoperative nausea and vomiting, use of anti-emetics, overall patient satisfaction, contact within 48 hours after surgery with general practicioner or emergency department and adverse events.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)